← Back to Analyst Consensus 
ELV Buy
Elevance Health, Inc.
Current Price —
Implied Upside —
Analysts 28
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 9 reiterations from 7 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 23, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| Oct 22, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Oct 22, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Oct 22, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Oct 22, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | — | 55% |
| Oct 22, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Oct 22, 2026 | Baird | maintain | Neutral → Neutral | — | 55% |
| Oct 12, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Oct 7, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Jul 17, 2026 | Bernstein | maintain | Outperform → Outperform | — | 52% |
| Jul 17, 2026 | Leerink Partners | maintain | Market Perform → Market Perform | — | 51% |
| Jul 16, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | — | 55% |
| Jul 16, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Jul 16, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jul 16, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Jul 16, 2026 | Baird | maintain | Neutral → Neutral | — | 55% |
| Jul 14, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| Jul 14, 2026 | Truist Securities | maintain | Buy → Buy | — | 55% |
| Jul 13, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Jul 9, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | — | 55% |
| Jul 7, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | — | 50% |
| Jul 2, 2026 | Bernstein | maintain | Outperform → Outperform | — | 52% |
| Jun 8, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Jun 8, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| Jun 4, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| Jun 4, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Jun 1, 2026 | Truist Securities | maintain | Buy → Buy | — | 55% |
| May 26, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| May 22, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| May 20, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| May 20, 2026 | Deutsche Bank | upgrade | Hold → Buy | — | 57% |
| Apr 29, 2026 | B of A Securities | upgrade | Neutral → Buy | — | 53% |
| Apr 28, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| Apr 24, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Apr 24, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Apr 24, 2026 | Bernstein | maintain | Outperform → Outperform | — | 52% |
| Apr 23, 2026 | Evercore ISI Group | maintain | In-Line → In-Line | — | 58% |
| Apr 23, 2026 | Baird | maintain | Neutral → Neutral | — | 55% |
| Apr 20, 2026 | Jefferies | maintain | Buy → Buy | — | 51% |
| Apr 13, 2026 | Truist Securities | maintain | Buy → Buy | — | 55% |
| Apr 8, 2026 | Evercore ISI Group | initiate | — → In-Line | — | 58% |
| Mar 11, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Feb 2, 2026 | JP Morgan | maintain | Overweight → Overweight | $397 | 55% |
| Feb 2, 2026 | Bernstein | maintain | Outperform → Outperform | — | 52% |
| Feb 2, 2026 | Truist Securities | maintain | Buy → Buy | $390 | 55% |
| Jan 30, 2026 | Barclays | maintain | Overweight → Overweight | $393 | 53% |
| Jan 30, 2026 | Wells Fargo | maintain | Overweight → Overweight | $391 | 54% |
| Jan 29, 2026 | Guggenheim | maintain | Buy → Buy | $396 | 52% |
| Jan 22, 2026 | Guggenheim | maintain | Buy → Buy | $414 | 52% |
| Jan 8, 2026 | Wolfe Research | upgrade | Peer Perform → Outperform | $425 | 54% |
Price Target Trend
Aug 3, 2026 Oct 27, 2026
EPS Estimates
+1y —
+1q —
0y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days